Radiation Oncology Group
EORTC 22952 – No Radiotherapy versus Whole Brain Radiotherapy for 1 to 3 Brain Metastases from Solid Tumor after Surgical Resection or Radiosurgery.
A Randomized Phase III Trial.
The role of whole-brain radiotherapy (WBRT) after either surgical resection or radiosurgery of brain metastases has been debated for many years. Previous studies have established a marginal advantage of WBRT for progression-free survival in patients with stable, solid brain tumors. However, because brain metastases cannot be cured and only symptoms can be treated, maintenance of health-related quality of life (HRQOL) is very important. Therefore, this EORTC study found that additional whole-brain radiotherapy (WBRT) after surgery or radiosurgery negatively impacts heath-related quality of life in patients with brain metastases. These results help to better inform patients and oncologists on treatment options.